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Abstract  27 
Background: Levothyroxine does not improve hypothyroid symptoms among adults with subclinical hypothyroidism 28 
(SCH). However, those with greater symptoms prior to treatment may still benefit. 29 
Objective: To determine whether levothyroxine improves hypothyroid symptoms and tiredness among older adults with 30 
SCH and greater symptom burden. 31 
Design: Secondary analysis of the randomized, placebo-controlled TRUST trial. 32 
Setting: Switzerland, Ireland, the Netherlands, Scotland. 33 
Participants: 638 persons ≥65 years with persistent SCH (thyrotropin 4.6-19.9mIU/L for >3months, normal free 34 
thyroxine) and complete outcome data. 35 
Intervention: Levothyroxine or matching placebo with mock dose-titration. 36 
Measurements: One year change in Hypothyroid Symptom and Tiredness scores (range 0-100, higher scores indicate more 37 
symptoms) on the Thyroid-Related Quality-of-Life Questionnaire among participants with high symptom burden (baseline 38 
Hypothyroid Symptoms score >30 or Tiredness score >40) vs. lower symptom burden. 39 
Results: 132 participants had Hypothyroid Symptoms score >30 and 133 had Tiredness score >40. Among the high 40 
symptom group, the Hypothyroid Symptoms score improved similarly between those on levothyroxine (mean within-group 41 
change -12.3, 95% CI -16.6 to -8.0) and those on placebo (-10.4, 95% CI -15.3 to -5.4) at 1 year; the adjusted between-42 
group difference was -2.0, 95% CI -5.5 to 1.5, p=0.27. Improvement in Tiredness scores were also similar between those on 43 
levothyroxine (within-group change -8.9, 95% CI -14.5 to -3.3) and those on placebo (-10.9, 95% CI -16.0 to -5.8), 44 
adjusted between-group difference 0.0, 95% CI -4.1 to 4.0, p=0.99. There was no evidence that baseline Hypothyroid 45 
Symptom score or Tiredness score modified the effects of levothyroxine vs. placebo (p for interaction=0.20 and 0.82, 46 
respectively). 47 
Limitation: Post-hoc analysis, small sample size, only examined patients with 1 year outcome data. 48 
Conclusion: In older adults with SCH and high symptom burden at baseline, levothyroxine did not improve hypothyroid 49 
symptoms or tiredness compared to placebo. 50 
Trial Registration: NCT01660126. 51 
Primary Funding Source: European Union FP7. 52 




Subclinical hypothyroidism, defined as elevated thyrotropin in combination with a normal free thyroxine,(1) is common, 55 
with a prevalence of up to 20% in older adults.(2) Following current guidelines from endocrine societies,(3, 4) subclinical 56 
hypothyroidism is often treated with levothyroxine.(5) This practice may contribute to levothyroxine being the most 57 
prescribed drug from 2014 onwards in the US,(5, 6) with more than 15% of Americans older than 61 years taking 58 
levothyroxine.(7) A recent large trial among older adults (TRUST trial), followed by a systematic review and meta-analysis 59 
of all randomized controlled trials observed no benefit of levothyroxine in patients with subclinical hypothyroidism in 60 
terms of symptoms or quality of life.(8, 9) 61 
It has been argued, however, that persons with subclinical hypothyroidism and greater symptoms may still benefit from 62 
levothyroxine treatment, because the majority of participants in clinical trials were asymptomatic or had only mild 63 
symptoms.(10, 11) This secondary analysis of the TRUST trial,(9) the largest randomized placebo-controlled trial of 64 
individuals with subclinical hypothyroidism to date, evaluated whether levothyroxine therapy improved hypothyroid 65 
symptoms and tiredness in older individuals with higher symptom burden at baseline. 66 
Methods 67 
Study design 68 
As previously reported,(9, 12) TRUST was a randomized, double-blind, parallel-group trial of levothyroxine versus 69 
placebo conducted from May 2014 until November 2016.(9) Participants were included from centers in Switzerland, 70 
Ireland, the Netherlands and Scotland. Randomization in a 1:1 ratio was performed using randomly permuted blocks with 71 
stratification by starting dose, country and sex. The randomization sequence was generated by the independent data center 72 
(Robertson Centre for Biostatistics, Glasgow).(12) 73 
Participants 74 
Participants were identified from clinical laboratory and Primary Care databases and records. Eligible persons were ≥65 75 
years old and presented with persistent subclinical hypothyroidism, defined as an elevated thyrotropin level (4.60 to 19.99 76 
mIU/L), measured at two separate timepoints ranging from 3 months to 3 years apart, in combination with a normal free 77 
thyroxine level. Reasons for participant exclusion were: current prescription of levothyroxine, antithyroid drugs, lithium, or 78 
amiodarone; thyroid surgery or receiving radioactive iodine in the last 12 months; hospitalization for an elective procedure 79 
or a major illness within the previous 4 weeks; acute coronary syndrome within the previous 4 weeks; clinical diagnosis of 80 




The study drug provided was either levothyroxine at a starting dose of 50 mcg daily (or 25 mcg in patients weighing <50 kg 83 
or with known coronary heart disease, i.e. previous myocardial infarction or symptoms of angina pectoris); or matching 84 
placebo. The levothyroxine dose was titrated to result in a thyrotropin level within the reference range of 0.40 to 4.59 85 
mIU/L. Participants in the placebo arm underwent mock titration to ensure blinding and aimed to deliver the same 86 
frequency of mock titrations as would be required in the levothyroxine treated group. All dose adjustments (in both 87 
levothyroxine and placebo treated groups) were automatically generated through a computer program at the Robertson 88 
Centre for Biostatistics in Glasgow (Scotland). In order to adequately blind the study, treating physicians, participants and 89 
investigators were unaware of the thyrotropin values during the course of the trial.(12)  90 
High symptom burden groups 91 
We defined four different high symptom groups based on patient reports on two quality of life measures (which were 92 
administered in English, French, German, or Dutch, as appropriate) and their performance on the handgrip test at baseline. 93 
We used cut-off points that approximated the most symptomatic quartile of participants in each group, based on baseline 94 
symptom scores derived from 638 participants who provided 1 year outcome data.  95 
The Thyroid-Related Quality-of-Life Patient-Reported Outcome measure (ThyPRO) questionnaire is a measurement tool 96 
for the assessment of health-related quality of life, with the best clinical validity and reliability in patients with benign 97 
thyroid disorders.(13, 14) ThyPRO was developed based on multi-trait scaling and internal consistency analyses.(15) It 98 
proved to be a reliable scale with complete convergent validity and almost complete discriminant validity across different 99 
clinical and sociodemographic subgroups.(13) We defined two groups of high symptom subjects based on scores on the 100 
Hypothyroid Symptoms score (4 items) and Tiredness score (7 items) from the ThyPRO questionnaire; these are scored 101 
from 0 to 100, with higher values indicating more hypothyroid symptoms or tiredness, respectively. In the absence of 102 
agreed upon cut-off points, we estimated a clinically significant threshold in collaboration with the developer of the 103 
ThyPRO questionnaire (Prof. Torquil Watt, co-author) and defined high symptom burden on the ThyPRO questionnaire as 104 
Hypothyroid Symptoms score >30 and Tiredness score >40 at baseline, respectively.  105 
Additionally, we used subjects’ EQ-5D Health Utility score as assessed by the EuroQoL (EQ) Group 5-Dimension Self-106 
Report Questionnaire (range 0.00 to 1.00) with higher score indicating higher QOL).(9, 16) Subjects with a score of <0.75 107 
for EQ-5D Health Utility were classified as having high symptoms. Handgrip strength was measured with a Jamar 108 
isometric dynamometer (best of three measurements in the dominant hand).(17) We determined a threshold of <20kg for 109 
handgrip strength as clinically significant threshold for our fourth high symptom burden group. Out of all of the TRUST 110 
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measures, we selected EQ-5D and handgrip strength because EQ-5D is the most comprehensive scale for quality of life 111 
available within TRUST, and handgrip strength is an objective measure of weakness.  112 
 113 
Outcome Measures 114 
The two main outcomes for this analysis were change in the Hypothyroid Symptoms score and Tiredness score from the 115 
Thyroid-Related Quality-of-Life Patient-Reported Outcome measure (ThyPRO) questionnaire assessed after 1 year.(13) 116 
The minimal clinically important difference for each score has been estimated as 9 points. Additional outcomes also 117 
assessed after 1 year included change in the EQ-5D Health Utility score [minimal clinically important difference of 118 
approximately 0.05],(18) and change in handgrip strength measured with a Jamar isometric dynamometer (best of three 119 
measurements in the dominant hand; no validated minimal clinically important difference exists).(17)  120 
Statistical Analysis 121 
For this secondary analysis, we included participants who provided outcome data at 1 year for the two main outcomes. 122 
Baseline characteristics were summarized by treatment group separately for participants in the high symptom burden group 123 
compared to other participants for each score. 124 
We used linear mixed effects regression with repeated measures to analyze Hypothyroid Symptoms scores collected at 125 
baseline, 6-8 week follow-up, and at 1 year. The model assumed no difference between randomized groups at baseline, and 126 
allowed for differences between treatment groups (levothyroxine vs. placebo), separately at 6-8 weeks and at 1 year. 127 
Different treatment effects were assumed for those with a high symptom burden at baseline (Hypothyroid Symptoms score 128 
>30 points) and for those without (Hypothyroid Symptoms score ≤30). The model was adjusted for the randomization 129 
stratification variables (sex, country and starting dose of levothyroxine), and included a random subject effect. Treatment 130 
effect estimates at 1 year are reported with 95% confidence intervals and are displayed graphically. A likelihood ratio test 131 
comparing this model to one with a common treatment effect at 1 year gave a test of treatment effect heterogeneity 132 
according to baseline symptom burden. Similar analyses were done regarding the Tiredness score (cut-off point >40), the 133 
EQ-5D Health Utility score (cut-off point <0.75), and handgrip strength (<20kg cut-off point). 134 
Four sensitivity analyses were carried out. First, we compared the treatment effect (levothyroxine vs. placebo) at 1 year in 135 
the subgroup of participants who had both a Hypothyroid Symptoms score >30 and a Tiredness score >40. Second, we 136 
additionally adjusted the main analyses for comorbid conditions showing baseline differences between the levothyroxine 137 
and placebo group i.e. ischemic heart disease, hypertension, diabetes mellitus and smoking. Third, we repeated the main 138 
analysis among participants with baseline thyrotropin values 7 to 9.9 mIU/L. Fourth, we repeated the analyses including 139 
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data from 31 participants who were previously excluded from the analysis because their visits took place outside of the pre-140 
specified visit window (±31 days at the 12 month follow-up).  141 
All statistical analyses were conducted using R for Windows v3.6.0. Linear mixed effects models were fitted using the lme 142 
function from the nlme package. Statistical tests were 2-sided and p<0.05 was considered significant. 143 
Role of the Funding Source 144 
The TRUST trial was predominantly financed through the European Union FP7 program. Merck (Darmstadt, Germany) 145 
provided levothyroxine and matching placebo tablets free of charge. The funder, the trial sponsors (NHS Greater Glasgow 146 
and Clyde Health Board and University of Glasgow, United Kingdom; University College Cork, Ireland; Leiden University 147 
Medical Center, the Netherlands; and University of Bern and Bern University Hospital, Switzerland), and Merck played no 148 
role in the design, analysis, or reporting of the trial. The main sponsor (NHS Greater Glasgow and Clyde Health Board) 149 
contributed to the writing of the protocol. None of the sponsors were involved in the analysis nor the reporting of the 150 
results. 151 
Results 152 
Of 2647 persons ≥65 years old with subclinical hypothyroidism screened, 1910 were excluded, mainly because subclinical 153 
hypothyroidism was not persistent; 737 participants underwent randomization and were assigned to receive either placebo 154 
or levothyroxine (see Appendix Figure 1). Ninety-nine participants were excluded from the main analysis; 68 were lost to 155 
follow-up, and 31 had their 12 month visit outside the pre-specified visit window (i.e., ±31 days). Among the 638 156 
participants included in this current study, 132 (20.7%) had a baseline Hypothyroid Symptoms score >30 points and 133 157 
(20.8%) had a baseline Tiredness score >40. Of note, 56 had both a baseline Hypothyroid Symptoms score >30 points and a 158 
baseline Tiredness score >40. Tables 1 and 2 present the baseline characteristics of our sample according to treatment 159 
assignment and high symptom burden based on their Hypothyroid Symptom Score and Tiredness Score on the ThyPRO 160 
questionnaire. Baseline characteristics were generally similar between the active treatment and the placebo groups except 161 
for the distribution of some comorbid conditions and smoking status. Of note, among the 99 participants who were 162 
excluded for this secondary analysis, 34 had a Hypothyroid Symptoms score >30 and 26 a Tiredness score >40, 163 
respectively. 164 
Thyrotropin levels at baseline and 1 year follow-up of the four high symptom burden groups are shown separately for the 165 
levothyroxine and placebo groups in Appendix Table 1. The proportion of participants with normal thyrotropin 166 
concentrations with placebo treatment after 1 year were numerically but not statistically significantly higher for the high 167 
symptom burden groups than for the remaining participants [48.4% vs. 39.8%, respectively, for Hypothyroid Symptoms 168 
(p=0.25) and 46.3% vs. 40.2% for Tiredness (p=0.40)]. 169 
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After 1 year, the adjusted between-group difference (levothyroxine vs. placebo) in the Hypothyroid Symptom score was -170 
2.0, 95%CI -5.5 to 1.5, p=0.27 among those with Hypothyroid Symptoms score >30 (Table 3). In the remaining 506 171 
participants (Hypothyroid Symptoms score ≤30), the adjusted between-group difference was 0.6, 95%CI -1. 6 to 2.7, 172 
p=0.62 (Table 3). Furthermore, when baseline Hypothyroid Symptoms scores were dichotomized into >30 points vs. ≤30 173 
points, there was no evidence that the effect of levothyroxine treatment differed between those with higher baseline scores 174 
compared to those with lower baseline scores (interaction p value =0.20).  175 
In the high symptom burden group with Tiredness score >40, after 1 year the adjusted between-group difference in the 176 
Tiredness score was 0.0 95%CI -4.1 to 4.0, p=0.99 (Table 3). In the remaining 505 participants (Tiredness score ≤40), the 177 
adjusted between-group difference was 0.5, 95%CI -2.0 to 3.0, p=0.69. Furthermore, when baseline Tiredness scores were 178 
dichotomized into >40 vs. ≤40, there was no evidence that the effect of levothyroxine treatment differed between those 179 
with higher baseline scores compared to those with lower baseline scores (interaction p value =0.81).  180 
Other Outcomes 181 
Among the 152 participants who had EQ-5D score <0.75 at baseline, the EQ-5D score didn’t change in the levothyroxine 182 
group and improved in the placebo group after 1 year (adjusted between group difference -0.093, 95%CI -0.129 to -0.057, p 183 
<0.001; Table 3), whereas no difference between levothyroxine and placebo was observed in the ≥0.75 group of EQ-5D 184 
(adjusted between group difference -0.002, 95%CI -0.026 to 0.023, p=0.90, interaction p-value <0.001) (Table 3). 185 
Furthermore, among the 125 participants with handgrip strength <20kg at baseline, there was no difference between the 186 
levothyroxine and the placebo group after 1 year (adjusted between-group difference 0.7, 95%CI -0.8 to 2.2, p=0.33; Table 187 
3) and no difference between levothyroxine and placebo was observed in the rest of participants with ≥20kg of handgrip 188 
strength (adjusted between group difference -0.3, 95%CI -1.1 to 0.6, p=0.53, interaction p-value =0.20; Table 3). Overall, 189 
there was no indication of levothyroxine benefit compared to placebo (Figure 1).  190 
Sensitivity analyses 191 
We performed a number of sensitivity analyses as detailed in Appendix Table 2. First, when comparing the treatment effect 192 
(levothyroxine vs. placebo) in the subgroup of participants who had both a Hypothyroid Symptoms score >30 and a 193 
Tiredness score >40 (n=56), there was no benefit of levothyroxine. Second, when we additionally adjusted for comorbid 194 
conditions showing baseline differences between levothyroxine and the placebo group, i.e. ischemic heart disease, 195 
hypertension, diabetes mellitus and smoking, there was no benefit of levothyroxine regarding any of the 4 outcome 196 
variables. Third, when the analyses were limited to the 20-29 participants with baseline thyrotropin levels between 7.0 and 197 
9.9 mIU/L results again remained similar for all 4 high symptom burden groups. The number of participants with baseline 198 
thyrotropin values ≥10 mIU/L was too small (26 /638 participants) to perform stratified analyses. Fourth, when we included 199 
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data from 31 participants previously excluded because the visit took place outside of the pre-specified visit window, the 200 
results again remained similar.  201 
Discussion 202 
In this secondary analysis of the TRUST trial, levothyroxine therapy did not improve measures of hypothyroid symptoms, 203 
tiredness, quality of life or handgrip strength to a greater extent than placebo after 1 year of treatment, even among those 204 
with high symptom burden at baseline. Of note, quality of life as assessed by EQ-5D Health Utility score appeared to 205 
improve to a lesser degree among those treated with levothyroxine than those treated with placebo. However, given the 206 
multiple comparisons made, we consider the possibility that this may represent a chance finding.  207 
Despite the lack of evidence from randomized clinical trials,(8) many believe that levothyroxine therapy benefits those with 208 
subclinical hypothyroidism and symptoms attributable to hypothyroidism. This may be one reason why symptomatic 209 
patients are under-represented in previous trials of subclinical hypothyroidism.(10) In the absence of evidence from 210 
randomized clinical trials specifically designed to examine persons with subclinical hypothyroidism and high symptom 211 
burden, the next best approach is to further analyze existing trial data. As shown in these analyses, our results do not 212 
support the hypothesis that the subgroup of adults with subclinical hypothyroidism and high symptom burden before 213 
treatment benefit from levothyroxine therapy. In this context, three aspects need special emphasis: First, participants who 214 
were above the clinically meaningful threshold for the Hypothyroid Symptoms score and the Tiredness score, respectively, 215 
in our study had substantially higher symptom scores compared to the general population(19) (Hypothyroid Symptoms 216 
score: 45 vs. 14 (SD 16) points; Tiredness score: 57 vs. 35 (SD 21) points). Moreover, our high Hypothyroid Symptoms 217 
subgroup also had a much higher mean Hypothyroid Symptoms score compared to a previous trial of 78 participants with 218 
subclinical (n=66) and overt (n=12) hypothyroidism(19) (45 vs. 27 points); and a comparable Tiredness score (57 vs. 58 219 
points). This indicates that participants in our study with high symptom burden were truly symptomatic. Second, our results 220 
with their corresponding 95% confidence intervals for the two main outcomes (Hypothyroid Symptoms and Tiredness) are 221 
not consistent with a beneficial effect that approaches the minimal clinically important difference of 9 points. Third, our 222 
high symptom subgroups treated with levothyroxine demonstrated comparable improvements in terms of Hypothyroid 223 
Symptoms scores and Tiredness scores to that of the placebo group. This may be due to regression to the mean, the natural 224 
history of subclinical hypothyroidism, or the placebo effect, and may explain why many individuals with symptomatic 225 
subclinical hypothyroidism as well as their treating physicians are convinced that levothyroxine is beneficial. Of note, 47% 226 
of participants in the main high symptom burden groups had normalization of serum thyrotropin concentrations with 227 
placebo treatment after 1 year, a finding described in other studies,(20, 21) but in the high symptom group at 1 year 228 
thyrotropin remained significantly different between levothyroxine (mean thyrotropin =3.5 mIU/L) and placebo group 229 
(mean thyrotropin =5.3 mIU/L). Interestingly, there were more women in the high symptom burden group than in the rest 230 
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of participants. It is possible that in general non-specific symptoms like fatigue, sensitivity to cold or dry skin are more 231 
commonly perceived and/or reported by elderly women than elderly men. For example, low energy was more common in 232 
women than men aged >65 years (22% vs 12%) in a study by Cheng et al.(22) 233 
Our analyses did have several limitations. First, this secondary analysis was not pre-specified in the original trial protocol. 234 
Second, the mean thyrotropin level in the levothyroxine group after 1 year of therapy was approximately 3.6 mIU/L across 235 
all 4 outcome groups measured in our secondary analysis. It is possible that more aggressive levothyroxine therapy leading 236 
to lower thyrotropin levels would confer benefit. Third, TPO antibody levels were not available and we could not determine 237 
if antibody status affects response to levothyroxine treatment. Fourth, the TRUST trial may not generalize to certain 238 
subgroups. For example, TRUST did not specifically recruit individuals with subclinical hypothyroidism reporting explicit 239 
hypothyroid symptoms and/or tiredness and cannot exclude the possibility that a rare subgroup with greater symptoms 240 
would benefit from levothyroxine therapy. Within our subgroups with high symptom burden at baseline, only 5/132 241 
participants with Hypothyroid Symptoms >30 score and 8/133 participants with Tiredness >40 score had a thyrotropin level 242 
≥10 mIU/L; numbers which are too low to allow for further statistical analyses. Only older adults (≥65 years) were 243 
included. Finally, 68 participants with potentially informative data were lost to follow-up.  244 
Conclusion 245 
In this secondary analysis of the TRUST trial, levothyroxine therapy as compared to placebo was not associated with an 246 
improvement in hypothyroid symptoms or tiredness in older adults with persistent subclinical hypothyroidism and high 247 
symptom burden at baseline. In the absence of another RCT specifically designed for persons with subclinical 248 
hypothyroidism and high symptom burden, these results do not support routine levothyroxine therapy among older 249 
individuals with subclinical hypothyroidism, including those with greater hypothyroid symptoms and tiredness.  250 
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